Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
ARWR - Arrowhead Pharmaceuticals, Inc.
Market Cap 3.52B P/E - EPS this Y -67.20% Ern Qtrly Grth -
Income -470.79M Forward P/E -13.24 EPS next Y 11.80% 50D Avg Chg -6.00%
Sales 35.47M PEG -1.06 EPS past 5Y - 200D Avg Chg -1.00%
Dividend N/A Price/Book 7.89 EPS next 5Y 7.33% 52W High Chg -32.00%
Recommedations 2.10 Quick Ratio 7.99 Shares Outstanding 124.20M 52W Low Chg 43.00%
Insider Own 4.48% ROA -32.07% Shares Float 110.70M Beta 0.78
Inst Own 79.52% ROE -99.43% Shares Shorted/Prior 9.61M/8.87M Price 32.97
Gross Margin 100.00% Profit Margin - Avg. Volume 906,422 Target Price 53.77
Oper. Margin -1,335.58% Earnings Date Aug 5 Volume 876,899 Change -2.11%
Healthcare | Biotechnology | United States
About Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Arrowhead Pharmaceuticals, Inc. News
05/16/24 ARWR: Summer Webinar Series to Highlight Development Pipeline…
05/10/24 Arrowhead Pharmaceuticals Reports Substantial Fiscal Q2 Loss, Diverging from Analyst Expectations
05/10/24 Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2024 Earnings Call Transcript
05/09/24 Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results
05/02/24 Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma
04/29/24 Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences
04/26/24 Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars
04/24/24 Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results
04/24/24 Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
04/16/24 Turnstone Biologics Appoints William Waddill to its Board of Directors
04/16/24 Institutional investors may adopt severe steps after Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) latest 6.6% drop adds to a year losses
04/07/24 Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo
04/04/24 Insider Sell: Chief Discovery/Trans Medicine James Hamilton Sells 6,000 Shares of Arrowhead ...
04/01/24 Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
03/25/24 Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data
03/11/24 The 3 Most Undervalued Russell 2000 Stocks to Buy in March 2024
03/08/24 Arrowhead Pharmaceuticals Inc CFO Kenneth Myszkowski Sells 40,000 Shares
03/08/24 Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
03/06/24 Is Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Expensive For A Reason? A Look At Its Intrinsic Value
03/04/24 Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences
ARWR Chatroom

User Image Nasfact Posted - 2 days ago

$ARWR Chart is going nicely... Sunday news might triggern up or down movement... If down I buy more.. Have been adding lately

User Image Rawtoast Posted - 2 days ago

$ARWR

User Image johnnygogogo Posted - 2 days ago

$ARWR adipose poster (“adiposter”) https://ir.arrowheadpharma.com/static-files/dc565fe1-998b-4cb2-99a3-6d89939a8c8a

User Image skeezbag Posted - 2 days ago

$ARWR any given Monday Chris can choke on a 🍌

User Image skeezbag Posted - 3 days ago

$ARWR of course it peaks at yesterday's floor. Games resume for the clown stock

User Image skeezbag Posted - 3 days ago

$ARWR the frauds at citadel increased position by 1165% to 740k shares

User Image John_Wick1234 Posted - 3 days ago

$ARWR Nice Double Bottom.

User Image skeezbag Posted - 3 days ago

$ARWR the fake dicerna market cap ceiling game still being played

User Image Rabinovich Posted - 4 days ago

$ARWR Avoro increasing is very good news. They were involved in some fascinating BOs.

User Image Swinging4Thefenc3 Posted - 4 days ago

$ARWR ridding this from $22-$32.. easy money

User Image SBL71 Posted - 4 days ago

$ARWR so Summer Slam 2024 kicks off with a bang next week and the main event is muscular...its a no holds barred, P1 candidate.

User Image skeezbag Posted - 4 days ago

$ARWR last chance to break the morning high and then the algo can take it back down sub $24

User Image StockScubaDiver Posted - 4 days ago

$ARWR

User Image johnnygogogo Posted - 4 days ago

$ARWR Avoro drank the Kool-Aid. 7% owner now. https://whalewisdom.com/stock/arwr

User Image biomarkets Posted - 4 days ago

$ARWR I buy at 20$

User Image NoFearHere Posted - 5 days ago

$ARWR it's always been a buy when it's been here

User Image flytrader1 Posted - 5 days ago

$ARWR big buyer of $35 call options in Sept!

User Image skeezbag Posted - 5 days ago

$ARWR clown stock 🤡

User Image Vpounder Posted - 5 days ago

$ARWR will finish red. Can't hold an 8.5% gain

User Image Steppinstone Posted - 5 days ago

$ARWR Love seeing hedge fund managers outraged at meme investing. These folks have a truck load of temerity.

User Image johnnygogogo Posted - 5 days ago

$ARWR me and @skeezbag waiting for the Morgan Scamley 13F to print

User Image SBL71 Posted - 5 days ago

$ARWR

User Image Rabinovich Posted - 5 days ago

$ARWR Nice little low volume rally. Sold some. Don't trust the CEO and the economy.

User Image LeftyT Posted - 5 days ago

$ARWR The unmet need for an FCS treatment is significant, and plozasiran is a proven winner here. Buried in the ER is a casual statement "last study visit for the last patient enrolled in PALISADE occurred about a week ago." Their first completed Phase 3 trial isn't worthy of a separate PR? Most CEO's would be doing backflips to highlight this, but Chris continues to be silent on real progress. Hmmm??

User Image johnnygogogo Posted - 5 days ago

$ARWR just a 613k~ share / 137%~ QoQ increase from Goldman. Nothing to see here folks. Move along. https://whalewisdom.com/stock/arwr

User Image Waitwhat Posted - 5 days ago

$ARWR CEO to be on the cover of the upcoming July issue of Missmanagment.

User Image SBL71 Posted - 5 days ago

$ARWR are we going to test or exceed the current 52 week low?

User Image SBL71 Posted - 6 days ago

$ARWR Just a shining light in my portfolio...oh wait, my bad, wrong board...

User Image putsandcalls Posted - 6 days ago

$ARWR someone will swoop in and buy this withering pos.

User Image StockScubaDiver Posted - 6 days ago

$ARWR

Analyst Ratings
Morgan Stanley Equal-Weight May 13, 24
HC Wainwright & Co. Buy May 13, 24
Chardan Capital Buy May 10, 24
HC Wainwright & Co. Buy Feb 8, 24
Citigroup Neutral Feb 7, 24
RBC Capital Outperform Feb 7, 24
Morgan Stanley Equal-Weight Feb 7, 24
RBC Capital Outperform Jan 16, 24
B of A Securities Buy Jan 2, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Jan 31 Sell 32.44 57,499 1,865,268 3,715,048 02/02/24
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Jan 31 Option 14.54 57,499 836,035 3,772,547 02/02/24
Hamilton James C Chief Discovery/Tran.. Chief Discovery/Trans Medicine Jan 12 Sell 36.92 7,940 293,145 210,851 01/17/24
GIVEN DOUGLAS B Director Director Jan 11 Sell 38.16 2,911 111,084 129,711 01/16/24
Waddill William D. Director Director Jan 11 Sell 38.2 3,934 150,279 47,870 01/16/24
Ferrari Mauro Director Director Jan 11 Sell 38.22 3,147 120,278 60,778 01/16/24
Vakiener Victoria Director Director Jan 11 Sell 38.36 4,720 181,059 32,001 01/16/24
Oliver Tracie Chief Commercial Off.. Chief Commercial Officer Jan 04 Sell 33.89 74 2,508 136,501 01/08/24
Myszkowski Kenneth Allen Chief Financial Offi.. Chief Financial Officer Jan 04 Sell 34.89 16,104 561,869 440,600 01/08/24
San Martin Javier Chief Medical Office.. Chief Medical Officer Jan 04 Sell 34.93 8,303 290,024 198,497 01/08/24
Hamilton James C Other Other Jan 03 Sell 33.89 38,443 1,302,833 218,791 01/05/24
O'Brien Patrick COO and General Coun.. COO and General Counsel Jan 03 Sell 33.46 33,190 1,110,537 464,385 01/05/24
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Jan 02 Sell 31 9,952 308,512 3,715,048 01/04/24
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Dec 20 Sell 28.54 12,000 342,480 3,725,000 12/22/23
San Martin Javier Chief Medical Office.. Chief Medical Officer Nov 20 Sell 28.87 19,700 568,739 131,800 11/22/23
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Oct 25 Sell 24.21 24,338 589,223 3,737,000 10/27/23
Vakiener Victoria Director Director Sep 28 Sell 26.33 1,550 40,812 21,734 10/02/23
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Sep 18 Sell 28.14 57,755 1,625,226 3,761,338 09/20/23
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Sep 18 Option 4.75 57,755 274,336 3,819,093 09/20/23
Oliver Tracie Chief Commercial Off.. Chief Commercial Officer Jul 03 Sell 35.31 8,925 315,142 61,575 07/06/23
Hamilton James C Other Other Jun 30 Sell 35.53 3,000 106,590 188,484 07/05/23
Myszkowski Kenneth Allen Chief Financial Offi.. Chief Financial Officer Jun 27 Sell 36.20 15,000 543,000 381,704 06/29/23
GIVEN DOUGLAS B Director Director May 05 Sell 40.90 6,500 265,850 117,635 05/08/23
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer May 03 Sell 39.38 104,928 4,132,065 3,761,338 05/05/23
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer May 03 Option 2.01 104,928 210,905 3,811,338 05/05/23
OLUKOTUN ADEOYE Y Director Director Mar 03 Sell 32.65 11,350 370,578 7,867 03/06/23
GIVEN DOUGLAS B Director Director Feb 27 Sell 32.62 875 28,542 13,000 03/01/23
Waddill William D. Director Director Jan 09 Sell 30 3,200 96,000 28,950 01/11/23
O'Brien Patrick COO and General Coun.. COO and General Counsel Jan 05 Sell 37.39 15,000 560,850 413,375 01/06/23
Hamilton James C Other Other Jan 05 Sell 37.4 13,803 516,232 191,484 01/06/23
Hamilton James C Other Other Jan 03 Sell 39.05 10,338 403,699 145,287 01/05/23
Myszkowski Kenneth Allen Chief Financial Offi.. Chief Financial Officer Dec 29 Sell 40.00 30,625 1,225,000 336,704 12/30/22
O'Brien Patrick General Counsel General Counsel Dec 21 Option 6.15 32,000 196,800 380,875 12/22/22
San Martin Javier Chief Medical Office.. Chief Medical Officer Nov 21 Sell 30.3 19,500 590,850 91,500 11/22/22
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Sep 27 Option 30.99 40,624 1,258,938 3,468,314 09/29/22
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Jul 07 Option 14.54 2,501 36,365 4,060,135 07/11/22
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Feb 11 Option 5.19 146,388 759,754 4,204,022 02/14/22
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Feb 11 Sell 51.7 146,388 7,568,260 4,057,634 02/14/22
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Jan 07 Option 5.19 11,806 61,273 4,057,634 01/07/22
O'Brien Patrick General Counsel General Counsel Jan 05 Sell 62.59 32,500 2,034,175 348,875 01/07/22
Myszkowski Kenneth Allen Chief Financial Offi.. Chief Financial Officer Jan 05 Sell 62.41 40,000 2,496,400 464,005 01/06/22
Hamilton James C Other Other Jan 04 Sell 64.84 25,625 1,661,525 155,625 01/06/22
GIVEN DOUGLAS B Director Director Dec 28 Buy 66.37 655 43,472 109,868 12/29/21
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Dec 15 Sell 68.28 60,000 4,096,800 3,219,022 12/17/21
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Oct 20 Sell 65.96 65,000 4,287,400 3,279,022 10/22/21
O'Brien Patrick General Counsel General Counsel Feb 10 Option 5.22 90,000 469,800 383,375 02/10/21
O'Brien Patrick General Counsel General Counsel Feb 10 Sell 88.34 90,000 7,950,600 293,375 02/10/21
Hamilton James C Other Other Jan 15 Sell 81.4 10,000 814,000 126,250 01/15/21
Myszkowski Kenneth Allen Chief Financial Offi.. Chief Financial Officer Jan 12 Sell 81.01 13,038 1,056,208 444,005 01/12/21
O'Brien Patrick General Counsel General Counsel Jan 07 Sell 71.91 25,000 1,797,750 293,375 01/07/21